Use of the Gepon immunomodulator for ulcerative colitis treatment

The efficacy of the Gepon immunomodulator was studied in 36 patients with ulcerative colitis (UC) having distal lesions in the resistant form. Taking into account the fact that immunological abnormalities play the main role in UC pathogenesis, the drug with immunomodulatory action was used for overc...

Full description

Saved in:
Bibliographic Details
Published inĖksperimental'nai͡a︡ i klinicheskai͡a︡ gastroėnterologii͡a no. 1; p. 14
Main Authors Malakhova, N S, Pichugin, A V, Khalif, I L, Ataullakhanov, R I
Format Journal Article
LanguageRussian
Published Russia (Federation) 2005
Subjects
Adjuvants, Immunologic - therapeutic use
Adult
Aged
CD8-Positive T-Lymphocytes - cytology
Colitis, Ulcerative - drug therapy
Colitis, Ulcerative - immunology
Female
Humans
Killer Cells, Natural - cytology
Male
Middle Aged
Peptides - therapeutic use
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:The efficacy of the Gepon immunomodulator was studied in 36 patients with ulcerative colitis (UC) having distal lesions in the resistant form. Taking into account the fact that immunological abnormalities play the main role in UC pathogenesis, the drug with immunomodulatory action was used for overcoming resistance to basic anti-inflammatory drugs. The clinical and immunological reaction to the used drugs was found to be ambiguous. Most of the patients (83.3%) had clinical and endoscopic amelioration after taking Gepon and managed to overcome the resistance to basic anti-inflammatory drugs.
ISSN:1682-8658